Sanibel Captiva Trust Company Inc. Has $541,000 Stock Holdings in Baxter International Inc. (NYSE:BAX)

Sanibel Captiva Trust Company Inc. lessened its stake in shares of Baxter International Inc. (NYSE:BAX) by 9.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,186 shares of the medical instruments supplier’s stock after selling 1,637 shares during the period. Sanibel Captiva Trust Company Inc.’s holdings in Baxter International were worth $541,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its position in Baxter International by 2.2% in the second quarter. Nisa Investment Advisors LLC now owns 95,997 shares of the medical instruments supplier’s stock worth $3,239,000 after purchasing an additional 2,072 shares during the period. ORG Partners LLC lifted its holdings in shares of Baxter International by 8,313.8% during the second quarter. ORG Partners LLC now owns 4,880 shares of the medical instruments supplier’s stock valued at $161,000 after acquiring an additional 4,822 shares during the period. SG Americas Securities LLC lifted its holdings in shares of Baxter International by 68.2% during the second quarter. SG Americas Securities LLC now owns 156,264 shares of the medical instruments supplier’s stock valued at $5,227,000 after acquiring an additional 63,352 shares during the period. Kingswood Wealth Advisors LLC increased its stake in shares of Baxter International by 4.6% in the second quarter. Kingswood Wealth Advisors LLC now owns 7,759 shares of the medical instruments supplier’s stock valued at $260,000 after buying an additional 343 shares in the last quarter. Finally, Burns Matteson Capital Management LLC acquired a new stake in shares of Baxter International in the second quarter valued at $287,000. 90.19% of the stock is owned by institutional investors.

Baxter International Stock Performance

NYSE:BAX traded up $0.07 during trading hours on Wednesday, reaching $36.29. The stock had a trading volume of 378,038 shares, compared to its average volume of 4,254,356. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.01 and a current ratio of 1.48. The stock has a 50 day simple moving average of $34.91 and a 200 day simple moving average of $37.75. Baxter International Inc. has a 12-month low of $31.01 and a 12-month high of $44.01. The stock has a market cap of $18.49 billion, a P/E ratio of 6.97, a price-to-earnings-growth ratio of 1.88 and a beta of 0.57.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.02. Baxter International had a return on equity of 18.47% and a net margin of 17.79%. The firm had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.75 billion. During the same quarter in the previous year, the company posted $0.55 earnings per share. The company’s revenue was up 2.8% compared to the same quarter last year. On average, research analysts forecast that Baxter International Inc. will post 2.91 EPS for the current fiscal year.

Baxter International Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 1st. Shareholders of record on Friday, August 30th will be issued a dividend of $0.29 per share. The ex-dividend date of this dividend is Friday, August 30th. This represents a $1.16 dividend on an annualized basis and a dividend yield of 3.20%. Baxter International’s dividend payout ratio (DPR) is 22.31%.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Morgan Stanley cut Baxter International from an “equal weight” rating to an “underweight” rating and reduced their target price for the stock from $39.00 to $30.00 in a report on Monday, July 15th. Evercore ISI reduced their target price on Baxter International from $46.00 to $45.00 and set an “outperform” rating on the stock in a report on Tuesday, July 2nd. StockNews.com upgraded Baxter International from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. The Goldman Sachs Group lifted their price objective on Baxter International from $36.00 to $40.00 and gave the company a “neutral” rating in a report on Thursday, August 8th. Finally, JPMorgan Chase & Co. cut their price objective on Baxter International from $44.00 to $42.00 and set a “neutral” rating on the stock in a report on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Baxter International currently has an average rating of “Hold” and an average target price of $41.73.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.